重症成人患者抗菌药物治疗药物监测:立场文件
该立场文件由欧洲重症医学会(ESICM)、欧洲临床微生物与感染病学会(ESCMID)药代动力学/药效学与危重患者研究组、国际治疗药物监测与临床毒理学协会(IATDMCT)及国际抗微生物化疗学会(ISAC)提名的专家组成员撰写,旨在回顾并讨论重症成人患者抗菌药物TDM的现有数据,并为常规临床实践中如何应用TDM提供实用指南。专家组认为,TDM指导给药对氨基糖苷类、伏立康唑和利巴韦林已显示临床获益;对ICU大多数常用抗生素和抗真菌药已建立明确治疗范围,常规TDM似乎有价值;抗病毒药尚需研究确定治疗目标及TDM是否有价值。专家组推荐对氨基糖苷类、β-内酰胺类抗生素、利奈唑胺、替考拉宁、万古霉素和伏立康唑在重症患者中常规开展TDM。结论指出,尽管TDM应成为每个ICU大多数抗菌药物的标准治疗,但在全球广泛实施常规TDM之前仍需解决重要障碍。
要点
- 专家组推荐对氨基糖苷类、β-内酰胺类抗生素、利奈唑胺、替考拉宁、万古霉素和伏立康唑在重症成人患者中常规开展TDM。
- TDM指导给药已显示对氨基糖苷类、伏立康唑和利巴韦林有临床获益。
- 对ICU大多数常用抗生素和抗真菌药已建立明确治疗范围,常规TDM似乎有价值。
- 抗病毒药尚需研究确定治疗目标及TDM在该人群中是否有价值。
- 尽管TDM应成为每个ICU大多数抗菌药物的标准治疗,但全球广泛实施前仍需解决重要障碍。
适用人群与场景
- 重症成人患者(ICU)
- 接受氨基糖苷类、β-内酰胺类抗生素、利奈唑胺、替考拉宁、万古霉素、伏立康唑、抗病毒药等抗菌药物治疗者
处置流程与药物剂量
- 专家组推荐对氨基糖苷类、β-内酰胺类抗生素、利奈唑胺、替考拉宁、万古霉素和伏立康唑在重症成人患者中常规开展TDM。
研究设计与关键结果
- TDM指导给药已显示对氨基糖苷类、伏立康唑和利巴韦林有临床获益。
- 对ICU大多数常用抗生素和抗真菌药已建立明确治疗范围,常规TDM似乎有价值。
- 抗病毒药尚需研究确定治疗目标及TDM在该人群中是否有价值。
证据类型、等级与局限
- 证据类型:由ESICM、ESCMID药代动力学/药效学与危重患者研究组、IATDMCT及ISAC提名的专家组成员进行文献回顾与分析并作出推荐(立场文件)。
- 局限:原文未报告局限性
对床旁实践的改变
- 专家组推荐在重症成人患者中常规开展TDM的抗菌药物包括氨基糖苷类、β-内酰胺类抗生素、利奈唑胺、替考拉宁、万古霉素和伏立康唑。
- 尽管TDM应成为每个ICU大多数抗菌药物的标准治疗,但在全球广泛实施常规TDM之前仍需解决重要障碍。
指南或共识出处
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper(Intensive Care Med),由ESICM、ESCMID药代动力学/药效学与危重患者研究组、IATDMCT及ISAC背书
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: This Position Paper aims to review and discuss the available data on therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients in the intensive care unit (ICU). This Position Paper also provides a practical guide on how TDM can be applied in routine clinical practice to improve therapeutic outcomes in critically ill adult patients.
METHODS: Literature review and analysis were performed by Panel Members nominated by the endorsing organisations, European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC). Panel members made recommendations for whether TDM should be applied clinically for different antimicrobials/classes.
RESULTS: TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established, and for these agents, routine TDM in critically ill patients appears meritorious. For the antivirals, research is needed to identify therapeutic targets and determine whether antiviral TDM is indeed meritorious in this patient population. The Panel Members recommend routine TDM to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients.
CONCLUSION: Although TDM should be the standard of care for most antimicrobials in every ICU, important barriers need to be addressed before routine TDM can be widely employed worldwide.
参考来源
- Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020. PMID: 32383061. doi:10.1007/s00134-020-06050-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。